Immunotherapy in non-small cell lung cancer: current status, advances and challenges

被引：0

作者：

Tartarone, Alfredo ^{[1
]}

Lerose, Rosa ^{[2
]}

Tartarone, Marina ^{[3
]}

机构：

[1] IRCCS CROB Referral Canc Ctr Basilicata, Dept Onco Hematol, Div Med Oncol, Via Padre Pio 1, I-85028 Rionero In Vulture, Potenza, Italy

[2] IRCCS CROB Referral Canc Ctr Basilicata, Hosp Pharm, Rionero In Vulture, Potenza, Italy

[3] Humanitas Univ, Milan, Italy

来源：

MINERVA RESPIRATORY MEDICINE | 2024年 / 63卷 / 03期

关键词：

Carcinoma; non-small-cell lung; Immunotherapy; Immune checkpoint inhibitors; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 1ST-LINE TREATMENT; BRAIN METASTASES; POOLED ANALYSIS; CHECKMATE; 9LA; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL; PHASE-3;

D O I：

10.23736/S2784-8477.24.02108-9

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

In recent years, thanks to the advent of immunotherapy, the therapeutic landscape of non-oncogene-addicted non-small cell lung cancer (NSCLC) has undergone a complete revolution. So far, several monoclonal antibodies directed against PD-1, PD-L1, or CTLA-4, known as immune checkpoint inhibitors (ICIs), administered alone or in combination with other agents have shown efficacy in metastatic setting as well as, more recently, even in the early-stage. We reviewed the role of immunotherapy in NSCLC focusing the attention not only on the results of the main currently available clinical trials but also on novel combination strategies.

引用

页码：110 / 120

页数：11

共 53 条

[1]

Akinboro O, 2022, J CLIN ONCOL, V40

[2] FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC [J].

Akinboro, Oladimeji ;

Larkins, Erin ;

Pai-Scherf, Lee H. ;

Mathieu, Luckson N. ;

Ren, Yi ;

Cheng, Joyce ;

Fiero, Mallorie H. ;

Fu, Wentao ;

Bi, Youwei ;

Kalavar, Shyam ;

Jafri, Samina ;

Mishra-Kalyani, Pallavi S. ;

Zirkelbach, Jeanne Fourie ;

Li, Hongshan ;

Zhao, Hong ;

He, Kun ;

Helms, Whitney S. ;

Chuk, Meredith K. ;

Wang, Min ;

Bulatao, Ilynn ;

Herz, Jonathan ;

Osborn, Blaire L. ;

Xu, Yuan ;

Liu, Jiang ;

Gong, Yutao ;

Sickafuse, Sharon ;

Cohen, Rebecca ;

Donoghue, Martha ;

Pazdur, Richard ;

Beaver, Julia A. ;

Singh, Harpreet .

CLINICAL CANCER RESEARCH, 2022, 28 (11) :2221-2228

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5]

Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605

[6] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[7] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[8]

Carbone DP, 2023, J Clin Oncol, V41, P17

[9] The role of PD-1 signaling in health and immune-related diseases [J].

Chen, Ru-Yue ;

Zhu, Yun ;

Shen, Yun-Yan ;

Xu, Qin-Ying ;

Tang, Han-Yun ;

Cui, Ning-Xun ;

Jiang, Lu ;

Dai, Xiao-Mei ;

Chen, Wei-Qing ;

Lin, Qiang ;

Li, Xiao-Zhong .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[10] Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study [J].

Cho, Byoung Chul ;

Abreu, Delvys Rodriguez ;

Hussein, Maen ;

Cobo, Manuel ;

Patel, Anjan J. ;

Secen, Nevena ;

Lee, Ki Hyeong ;

Massuti, Bartomeu ;

Hiret, Sandrine ;

Yang, James Chih Hsin ;

Barlesi, Fabrice ;

Lee, Dae Ho ;

Ares, Luis Paz ;

Hsieh, Robert W. ;

Patil, Namrata S. ;

Twomey, Patrick ;

Yang, Xiaoying ;

Meng, Raymond ;

Johnson, Melissa L. .

LANCET ONCOLOGY, 2022, 23 (06) :781-792

← 1 2 3 4 5 6 →